Technology Offer Summary Point of care analyzer for definitive cystic fibrosis diagnostics A Barcelona based company offers a CE (Conformité Européenne) marked diagnostic test system for the measurement of chloride in sweat, providing a highly valuable test system for cystic fibrosis centers for the confirmation of cystic fibrosis in newborns. License agreement, manufacturing agreement, commercial agreement with companies and technical assistance with academical institutions are sought. Creation Date 03 January 2014 Last Update 01 August 2014 Expiration Date 01 August 2015 Reference 12 ES 252K 3NZG Details Description The sweat chloride concentration (SCC) remains the gold standard measure for confirming the diagnosis of Cystic Fibrosis (CF) and should be performed properly. In newborn babies the amount of sweat collected to determine chloride concentration may not be accurate and delay the diagnosis. The company designed a new analyser device for the direct measurement of sweat chloride concentration in very small quantities of sample. The company's sensitive sensors cards stimulate sweat pilocarpine iontophoresis and measures the chloride by ion selective electrodes. Thus, the test have very low rate of QNS (quantity not sufficient) may allow the commencement of treatments early after onset of the cystic fibrosis diagnostics and may also serve as a tool to control the efficiency of new therapy. The company seeks for companies able to monitor the tests and academical institutions for clinical validation of the results. Current and Potential Domain of Application: Cystic fibrosis units. Laboratory hospitals. Doctor office. Advantages and Innovations This new device reduces the time for the patient's test, simplifies the labour for the operators and offers more accuracy in the measurement. The sensors cards are manufactured with a specific chemical formula for the hidrogels on the sensors. Sensors are characterized for the measurement in the physiological range of chloride in sweat. Data are transmited to the base by readiofrequency, so there is no need to use cables while being monitored. Page 1 of 9
Stage of Development Already on the market IPR Status Copyright Profile Origin Private (in-house) research Keywords Technology 006001014 Medical Technology / Biomedical Engineering Market 005001008 Diagnostic test products and equipment NACE Q.86.1.0 Q.86.2.1 Q.86.2.2 Hospital activities General medical practice activities Specialist medical practice activities Dissemination Send to Sector Group Healthcare Client Type and Size of Organisation Behind the Profile Industry SME 11-49 Year Established 0 Already Engaged in Trans-National Cooperation No. Langages Spoken Page 2 of 9
English Spanish Partner Sought Type and Role of Partner Sought - Type of partner sought: companies, academical institution - Specific area of activity of the partner: Companies: medical devices; Academical: Cystic Fibrosis diagnostics - Task to be performed: Test monitoring for companies Clinical Validation for academicals Type and Size of Partner Sought SME 51-250 Type of Partnership Considered License agreement Manufacturing agreement Commercial agreement with technical assistance Technical cooperation agreement Page 3 of 9
Technology Offer Novel probes for simultaneous detection of virus related to respiratory infections Summary Two Spanish public research organizations have developed a new method, based on probes for DNA hybridization, for the detection of several viruses related to respiratory infections. The method can detect a wide variety of viruses, like influenza virus or synclinal respiratory virus among others, in a rapid and specific way. The probes could be adapted to different formats for infection diagnostics. Biotech or pharmaceutical companies are sought for further development under a licence agreement. Creation Date 28 July 2014 Last Update 01 August 2014 Expiration Date 01 August 2015 Reference TOES20130730002 Details Description Respiratory system infections are related to different types of virus (and also bacteria), and in some risk groups like elderly people, infant and inmunodepressed individuals, can cause an elevated mortality. From a clinical point of view, is difficult to distinguish their origin only by their symptoms. In this sense, the development of rapid and selective diagnostic methods is of great interest in order to take the appropriate curative measures. Nowadays, diagnostics methods are mainly based on traditional methods, like isolation from cell cultures or immunofluorescence techniques. Although these techniques are sensible, they are not selective enough to detect different types of virus in a same sample and therefore a co-infection. Genomic methods, like hybridization or PCR, are also used for virus detection, but several problems are related to their use: when the amount of sample is low, hybridization is not sensible enough; in the case of PCR, false positive can be produced by the contamination of adjacent samples (separated laboratories are needed in the amplification process); on the other hand, a limited number of different viruses can be detected simultaneously. The research group has developed a new method, based on a hybridization platform, which is very useful for the selective detection of virus related to respiratory infections. The method is rapid, sensible and with a great specificity: allows not only the detection and identification of the virus that causes the respiratory disease, but which further simultaneously enables its typing. The platform, based on oligonucleotides probes fixed on a solid support, could be transformed into a kit for analysis; an amplification reaction can be carried out before the hybridization in order to increase the sensibility. A wide range of different virus can be detected: Influenza virus, human respiratory Page 4 of 9
syncytial virus, human adenovirus, human parainfluenza virus, enterovirus, rhinovirus, human coronavirus and metapneumovirus. Advantages and Innovations The system allows not only the detection and characterization of the different viruses but also to know if they are sensible or resistant to antivirals. The viral amount on each sample can be quantified in order to monitor, in real time, the efficacy of the treatment on patients. The method is more rapid, sensible and specific than common diagnostic methods such as cell cultures or immunofluorescence. Can be easily implemented for routine analysis, and adapted to different formats (such as analysis kits). Can be applied to different samples, independently their transport and storage conditions. Compared to common PCR techniques, ambient contamination is reduced and therefore no separate laboratories are needed for the analysis. Co-infection produced by different viruses can be monitored in order to carry out epidemiological studies. Stage of Development Under development/lab tested IPR Status Patents granted Comment Regarding IPR status Patent granted in Spain Profile Origin National R&D programme Keywords Technology Market NACE 006001006 Diagnostics, Diagnosis 006001019 Virus, Virology / Antiobiotics / Bacteriology 006003002 Gene Expression, Proteom Research 002007012 Medical/health 005001010 Molecular diagnosis 005003005 Hospital and other institutional management (including management services and leasing) Q.86.1.0 Hospital activities Page 5 of 9
Client Type and Size of Organisation Behind the Profile R&D Institution Year Established 0 Already Engaged in Trans-National Cooperation No. Langages Spoken English Spanish Partner Sought Type and Role of Partner Sought Type of partner sought:pharmaceutical and biotech companies working in the field of virus diagnostics. Role of partner: Adapt and develop the technology for their commercialization Type of Partnership Considered License agreement Page 6 of 9
Technology Request Minimally invasive surgery: removal device for hardened calcifications sought Summary A medical research centre at a university hospital, specialist on minimally invasive surgery, is looking for a device that removes hardened calcifications caused by vascular occlusions. They are seeking companies, universities or research institutes for technical cooperation agreements. Creation Date 21 July 2014 Last Update 31 July 2014 Expiration Date 31 July 2015 Reference TRDE20140721001 Details Description Thrombosis is a common disease. 2 of 1000 people are taken ill in the western hemisphere every year. There are several treatments depending on the degree of the disease, which still show improvement potentials. Beside treatments like compression therapies or a anticoagulant substances-treatment for example with Heparin, there are several surgical thrombosis removal treatments, called thrombectomy. Thrombosis can lead to a vascular occlusion with heavy calcifications. This stadium can be very dangerous and risky to the patient s life. Currently multiple complicated surgeries are needed in order to remove these hardened calcifications. This treatment is very cost-intensive and for the patient painful and physically strenuous. A German medical research centre at a university hospital is looking for a device to remove hardened calcifications caused by vascular occlusions. They are seeking companies, universities or research institutes for technical cooperation agreements. Technical Specification or Expertise Sought The device should be able to remove easily complete hardened calcifications caused by vascular occlusions with one surgical intervention. Stage of Development Available for demonstration IPR Status Copyright Page 7 of 9
Keywords Technology 006001018 Surgery Market 005007003 Surgical instrumentation and equipment NACE Q.86.1.0 Hospital activities Dissemination Send to Sector Group Healthcare Client Type and Size of Organisation Behind the Profile University Year Established 0 Already Engaged in Trans-National Cooperation No. Langages Spoken English German Spanish Partner Sought Type and Role of Partner Sought The medical research institute is looking for partners in the field of medical technology. The specific area of the partner should be engineering and development. With the cooperation the specific needs of the customers of the partner can be adjusted. The device should be able to remove easily complete hardened calcifications caused by vascular occlusions with one surgical intervention. Page 8 of 9
Type and Size of Partner Sought >500 Type of Partnership Considered Technical cooperation agreement Page 9 of 9